drugset / Trial / NCT04269811
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease
NaSingle-groupOpen-labelTreatment
Summary
For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan
Timeline
- Start
- 2020-01-15
- Primary completion
- 2023-03-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | — |
| Subject | Flu-Bu-Mel | Unknown | 50 mg/m2 | — |
| Subject | Flu-Bu-Mel | Unknown | 70 mg/m2 | — |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
Indications
No indication recorded.